Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease. NAFLD is considered a multifactorial disease and a clinically relevant hepatic manifestation of metabolic syndrome. NAFLD is often accompanied by a constellation of metabolic and non-metabolic alterations, like dyslipidemia, insulin resistance in the liver and peripheral tissues, inflammation and oxidative stress; therefore, treatment of NAFLD should be directed at correcting all of these disturbances. The natural polyphenol curcumin has been the subject of increasing research for the treatment of NAFLD due to its lipid-modifying, antioxidant, anti-inflammatory, insulinsensitizing, anti-steatotic, and anti-fibrotic properties. The therapeutic efficacy of curcumin has been demonstrated in several experimental models of NAFLD, however, clinical evidence is still scarce. The present review summarizes the current knowledge on the impact of curcumin supplementation on different biochemical and histopathological features of NAFLD.
Keywords: Curcumin, steatosis, non-alcoholic steatohepatitis, dyslipidemia, inflammation.
Current Pharmaceutical Design
Title:Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes
Volume: 23 Issue: 7
Author(s): Narges Amel Zabihi, Matteo Pirro, Thomas P. Johnston and Amirhossein Sahebkar
Affiliation:
Keywords: Curcumin, steatosis, non-alcoholic steatohepatitis, dyslipidemia, inflammation.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease. NAFLD is considered a multifactorial disease and a clinically relevant hepatic manifestation of metabolic syndrome. NAFLD is often accompanied by a constellation of metabolic and non-metabolic alterations, like dyslipidemia, insulin resistance in the liver and peripheral tissues, inflammation and oxidative stress; therefore, treatment of NAFLD should be directed at correcting all of these disturbances. The natural polyphenol curcumin has been the subject of increasing research for the treatment of NAFLD due to its lipid-modifying, antioxidant, anti-inflammatory, insulinsensitizing, anti-steatotic, and anti-fibrotic properties. The therapeutic efficacy of curcumin has been demonstrated in several experimental models of NAFLD, however, clinical evidence is still scarce. The present review summarizes the current knowledge on the impact of curcumin supplementation on different biochemical and histopathological features of NAFLD.
Export Options
About this article
Cite this article as:
Zabihi Amel Narges, Pirro Matteo, Johnston P. Thomas and Sahebkar Amirhossein, Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes, Current Pharmaceutical Design 2017; 23 (7) . https://dx.doi.org/10.2174/1381612822666161010115235
DOI https://dx.doi.org/10.2174/1381612822666161010115235 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents
Current Pharmaceutical Biotechnology Stages of HIV Replication and Targets for Therapeutic Intervention
Current Topics in Medicinal Chemistry Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor)
Current Molecular Medicine Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]
Current Pharmaceutical Design Vesicular Nucleotide Transport: A Brief History and the Vesicular Nucleotide Transporter as a Target for Drug Development
Current Pharmaceutical Design Sleepiness, Sleep Disorders and Attention-Deficit/Hyperactivity Disorder: Pathophysiological Rationale and Future Perspectives
Current Psychiatry Reviews Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology The New Era of Nutraceuticals: Beneficial Effects of Polyphenols in Various Experimental and Clinical Settings
Current Pharmaceutical Design Uric Acid and the Kidney: Urate Transport, Stone Disease and Progressive Renal Failure
Current Pharmaceutical Design Advances on PPARγ Research in the Emerging Era of Precision Medicine
Current Drug Targets Glycemic Goal for Older Adults with Diabetes and Concentrated Basal Insulin Options
Applied Clinical Research, Clinical Trials and Regulatory Affairs Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Evaluation of Adverse Drug Event Information in US Manufacturer Labels
Current Drug Safety Variation of Pharmacokinetic Profiles of Some Antidiabetic Drugs from Nanostructured Formulations Administered Through Pulmonary Route
Current Drug Metabolism Mitochondria Associated Membranes (MAMs): Emerging Drug Targets for Diabetes
Current Medicinal Chemistry Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry